Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Affymetrix Inc.

Nov 2008
Affymetrix Inc. of Santa Clara, Calif., has signed an agreement with Medical Prognosis Institute A/S of Horsholm, Denmark, to develop and commercialize microarray-based drug-sensitivity prediction and prognostic products for patients with cancer. The agreement grants the institute nonexclusive access to the company’s microarray technology. The institute hopes to obtain regulatory clearance and to achieve commercialization within two years.

The technology also is being used by Wellcome Trust Sanger Institute of Hinxton, UK, to catalog the structural genomic changes in nearly 800 cancer cell lines. The information will enable the institute to advance understanding of the disease and may assist with diagnoses and treatment options in the future.

Affymetrix Inc.BiophotonicsmicroarrayResearch & Technology

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!